Company: Brace Pharmaceuticals
Liaison(s): Thiago Brasil, Vinzenz Ploerer
Brace Pharmaceuticals, Inc., is an investment company created by EMS S/A, the largest pharmaceutical company in Brazil. Brace Pharmaceuticals is looking for partners interested in co-developing pharmaceutical products that complement its corporate and product development strategy. These opportunities include innovative, life-changing therapies for diseases with high unmet medical need, including orphan diseases. Brace Pharmaceuticals intends to diversify its project portfolio by investing 80% of its funds in late-stage clinical phase projects and 20% in earlier phase projects. Brace’s initial investments have been completed and evaluation of additional feasible projects is ongoing. The Brace TMP’s main objective was to identify a short-list of projects that complement Brace’s investment strategy in the area of rare diseases. The team focused its initial efforts on evaluating potential candidates that have been granted orphan designations, orphan product approvals and/or awarded FDA grants to support clinical studies for rare diseases. These viable candidates were then analyzed based on scientific and medical rationale, regulatory considerations, intellectual property rights, and commercial potential. Future efforts will focus on identification and evaluation of candidates which have been approved in other markets.